Form 4: Insmed CFO Sara Bonstein Reports Acquisition of Stock Options and Restricted Stock Units

Sara Bonstein, CFO of Insmed Inc., reports the acquisition of stock options and restricted stock units (RSUs) in a recent Form 4 filing.

Summary

• On May 15, 2025, Sara Bonstein, the Chief Financial Officer of Insmed Inc., acquired 6,508 Restricted Stock Units (RSUs) and 31,610 stock options.
• The RSUs were granted under the company's Amended and Restated 2019 Incentive Plan and vest over four years, starting with 25% on the first day of the month following the first anniversary of the grant date, and then 25% annually.
• The stock options, also granted under the same incentive plan, vest with 25% on the initial vesting date and an additional 12.5% every six months thereafter until fully vested, and have an exercise price of $67.22.
• Following these transactions, Bonstein directly owns 114,867 shares of Insmed Inc. common stock, as well as 31,610 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing indicating standard executive compensation practices. The acquisition of equity can be seen as a positive sign of confidence, but it's not overwhelmingly positive.

Positives

• The acquisition of RSUs and stock options by the CFO could be seen as a positive sign, indicating confidence in the company's future performance.
• The vesting schedules for both RSUs and stock options incentivize long-term commitment from the CFO.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track management's alignment with shareholder interests.

Comparison to Industry Standards

• Equity compensation is a common practice among publicly traded companies, particularly in the biotechnology sector, to attract and retain key executives.
• Vesting schedules similar to those described in the document are typical, designed to incentivize long-term performance and commitment.
• Comparing the size of the equity grants to those of CFOs at comparable companies (e.g., BioMarin Pharmaceutical, Vertex Pharmaceuticals) would provide further context on the competitiveness of Insmed's compensation practices.

Stakeholder Impact

• The acquisition of equity by the CFO aligns her interests with those of shareholders, potentially encouraging decisions that benefit the company's long-term value.
• Employees may view the equity grants as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

Form 4, Insmed, Sara Bonstein, CFO, Restricted Stock Units, Stock Options, Beneficial Ownership, Incentive Plan, Vesting